Ferreira, Ederlan S. [UNESP]Silva, Maraiza A. [UNESP]Demonte, Aureluce [UNESP]Neves, Valdir Augusto [UNESP]2014-05-272014-05-272012-01-16Lipids in Health and Disease, v. 11.1476-511Xhttp://hdl.handle.net/11449/73170Background: There is increasing interest in non-pharmacological control of cholesterol and triglyceride levels in the plasma and diet-drug association represent an important area of studies. The objective of this study was to observe the hypocholesterolemic effect of soybean β-conglycinin (7S protein) alone and combined with fenofibrate and rosuvastatin, two hypolipidemic drugs. Methods. The protein and drugs were administered orally once a day to rats and the effects were evaluated after 28 days. Wistar rats were divided into six groups (n = 9): hypercholesterolemic diet (HC), HC+7S protein (300 mg.kg-1 day-1) (HC-7S), HC+fenofibrate (30 mg.kg-1 day-1)(HC-FF), HC+rosuvastatin (10 mg.kg-1 day-1)(HC-RO), HC+7S+fenofibrate (HC-7S-FF) and HC+7S+rosuvastatin (HC-7S-RO). Results: Animals in HC-7S, HC-FF and HC-RO exhibited reductions of 22.9, 35.8 and 18.8% in total plasma cholesterol, respectively. In HC-7S-FF, animals did not show significant alteration of the level in HC+FF while the group HC-7S-RO showed a negative effect in comparison with groups taking only protein (HC-7S) or drug (HC-RO). The administration of the protein, fenofibrate and rosuvastatin alone caused increases in the plasma HDL-C of the animals, while the protein-drug combinations led to an increase compared to HC-FF and HC-RO. The plasma concentration of triacylgycerides was significantly reduced in the groups without association, while HC-7S-FF showed no alteration and HC-7S-RO a little reduction. Conclusion: The results of our study indicate that conglycinin has effects comparable to fenofibrate and rosuvastatin on the control of plasma cholesterol, HDL-C and triacylglycerides, when given to hypercholesterolemic rats, and suggests that the association of this protein with rosuvastatin alters the action of drug in the homeostasis of cholesterol. © 2012 Ferreira et al; licensee BioMed Central Ltd.engβ-conglycinincholesterol-lowering drugshypercholesterolemic dietrats.beta conglycininfenofibratehigh density lipoprotein cholesterolrosuvastatinsoybean proteintriacylglycerolunclassified drugbeta conglycinin protein, Glycine maxbeta-conglycinin protein, Glycine maxcholesterolfluorobenzeneglobulinhypocholesterolemic agentplant antigenpyrimidine derivativeseed storage proteinsulfonamideanimal experimentanimal modelcholesterol blood levelcontrolled studydiethypercholesterolemiahypocholesterolemiamalenonhumanrattriacylglycerol blood levelanimalblooddrug combinationdrug effectdrug potentiationheartheart muscleisolation and purificationlipid dietlivermetabolismorgan sizepathologyprotein intakesoybeanWistar ratAnimaliaGlycine maxRattusRattus norvegicusAnimalsAnticholesteremic AgentsAntigens, PlantCholesterolDiet, High-FatDietary ProteinsDrug CombinationsDrug SynergismFenofibrateFluorobenzenesGlobulinsHeartHypercholesterolemiaLiverMaleMyocardiumOrgan SizePyrimidinesRatsRats, WistarSeed Storage ProteinsSoybean ProteinsSoybeansSulfonamidesTriglyceridesArtigo10.1186/1476-511X-11-11Acesso aberto2-s2.0-848557357832-s2.0-84855735783.pdf52699697678453534031319519910419